Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
The stream of top executives who make a detour to BusinessWeek Towers (and our offices around the world) to chat about strategy, business and plans for the future is impressive and unending. Our readers are smart, opinionated and passionate. In order to join the dots, we’re launching a new feature in which our readers get to ask the questions and set the agenda for a Q&A video interview. Each week, a reporter will put five — attributed — reader questions to the executive in the hot seat, asking follow-up questions where necessary.
First up, senior writer Arlene Weintraub will put your questions to Dr Roger M. Perlmutter, executive vice president of R&D at Amgen, the world’s largest biotechnology company. He’s coming in on Thursday 6 November; we’ll post the video the following week.
Below is some blurb from Arlene about why Perlmutter matters. If you have a question for him, please post in the comments — with your full name as you’d like to be credited, and your location too. Thanks for supporting our new venture!
An M.D., Ph.D. and former biology professor, Perlmutter worked for four years at Merck before joining Amgen in 2001. It was a perilous time. The Thousand Oaks (Calif.) company had risen to prominence on two pioneering drugs, one to treat anemia and the other to prevent infections in patients undergoing chemotherapy. But it didn’t have much in the pipeline to guarantee growth going forward. So Perlmutter re-thought research, seeking new ways to streamline the process and to look for good partners outside Amgen’s walls. There are early signs that it may be working: Amgen could file for FDA approval for a new osteoporosis drug in early 2009, and late-stage trial results suggest it could be a blockbuster. The company’s stock has risen 28% this year to $60 a share, even as the broader pharmaceutical indices have been falling.
Got a question for Roger? Ask it!
What comes next? The Bloomberg Businessweek Innovation and Design blog chronicles new tools for creativity and collaboration, innovation case studies in both the corporate and social sectors, and the new ideas that have the power to change the way things have always been done.